Capstan Therapeutics

Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D

Oct. 10 | 9:30am | Rentschler ATMP Ballroom 

San Diego, CA


Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders.

By using this website you agree to accept our Privacy Policy and Terms & Conditions